SCHEMBL21389517

SCHEMBL21389517

CCn1c(COc2ccc(C3NC(C(=O)O)CS3)cc2)nc2c1c(=O)[nH]c(=O)n2Cc1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ BRD4 O60885 3/20 0.45
▸ BRD2 P25440 2/20 0.45
▸ BRD3 Q15059 2/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ BRDT Q58F21 1/20 0.42
▸ TPH1 P17752 5/20 0.41
▸ TPH2 Q8IWU9 5/20 0.41
▸ HRH3 Q9Y5N1 1/20 0.41
▸ S1PR3 Q99500 1/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ MAPT P10636 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19090403 0.94 KMT2A (0.47) KMT2AMEN1ALDH1A1KDM4EALOX15
SCHEMBL19090561 0.87 HRH3 (0.46) KMT2AMEN1ALDH1A1KDM4EALOX15
SCHEMBL21389585 0.73 KMT2A (0.53) KMT2AMEN1BRD4BRD2BRD3
SCHEMBL19090597 0.72 ALDH1A1 (0.45) KMT2AMEN1ALDH1A1KDM4EALOX15
SCHEMBL21389578 0.72 MEN1 (0.83) KMT2AMEN1BRD4BRD2BRD3
SCHEMBL21389582 0.72 KMT2A (0.51) KMT2AMEN1BRD4BRD2BRD3
SCHEMBL21389579 0.71 MEN1 (0.66) KMT2AMEN1BRD4BRD2BRD3
SCHEMBL21389565 0.71 KMT2A (0.56) KMT2AMEN1BRD4BRD2BRD3
SCHEMBL19090335 0.70 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1KDM4EALOX15
SCHEMBL21389560 0.70 MEN1 (0.51) KMT2AMEN1BRD4BRD2BRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11225481-B2 Xanthine derivative inhibitors of BET proteins CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-01-18 — — US disclosed
EP-3397640-B1 XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS INST NAT SANTE RECH MED (FR) 2021-08-04 — — EP disclosed
US-20190292186-A1 XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-09-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292186-A1 XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS BET1, BRD4, BRD3 KMT2A 543/4885MEN1 3816/4885BRD4 2/4885
US-11225481-B2 Xanthine derivative inhibitors of BET proteins BET1, BRD4, BRD3 KMT2A 543/4885MEN1 3816/4885BRD4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback